Description
Pidnarulex (also known as CX-5461) is an experimental drug currently being studied in clinical trials for certain types of colorectal cancer. It is being investigated specifically for patients with microsatellite stable (MSS) colorectal cancer that has spread to the liver and does not respond to current treatments (refractory). Trials are evaluating pidnarulex both by itself and in combination with another immunotherapy drug called cemiplimab. The goal is to see if pidnarulex can help slow cancer growth (progression-free survival) and potentially improve overall survival in these patients. These trials are in the early phase (Phase 1), focusing on determining the right dose and assessing safety.
Mechanism of Action
Pidnarulex is designed to target a specific process within cancer cells. It interferes with the early steps of protein production, specifically targeting the ribosome before it is fully assembled. By disrupting this process, pidnarulex aims to stop cancer cells from growing and multiplying. The specific molecular target is being characterized in clinical trials.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.